Goodwin advised TCR2 Therapeutics on the completion of its highly oversubscribed $125 million Series B financing round. Proceeds of the financing will be used to advance…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
